Licensing: Holder of novel synthetic lethal factors
Joint research: Expecting, but not limited to, 1–3 years
To be discussed based on proposals
How to Apply Click on "Respond", complete the form to the extent possible, and submit along with other attachment files available. After creating your account for NineSights, your draft will be automatically saved and you can resume later from "Control Center". Please note you do not submit confidential information at this process. This request for proposals in PDF format is available here.
SOLUTION PROVIDER HELP DESK If you have any questions or request, please feel free to contact us at: firstname.lastname@example.org
RFP was closed on
Technology Platform to Discover Novel Synthetic Lethal Factors
NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/)(“Client”), seeks atechnology platform to discover synthetic lethal factors that can serve as the target for drug discovery.
The Client has advantages in cancer research. Through cooperation with the proposer, they aim at discovering a novel synthetic lethal factor(s) using proposer’s technology platform and finally creating innovative next-generation molecularly targeted anti-cancer drugs.
In addition to proposals on technology platform, this RFP also welcomes those on novel synthetic lethal factors discovered using the technology platform.
Key Success Criteria
The Client expects a proposal that meets one or both of the following items: (1) technology platform and (2) novel synthetic lethal factors.
(1) Technology platform
Requirements for technology platform are as follows:
The following criteria No. 1 and 2, and preferably No. 3 must be met:
Able to modify target genes accurately and comprehensively
e.g., Gene editing technology
Able to evaluate the synthetic lethal phenotype effectively
e.g., Screening using siRNA
Able to identify synthetic lethal genes from big data analysis
e.g., Analysis technique using AI (artificial intelligence) capable of processing/analyzing massive amounts of data including the existing information on genetic mutations and experimental data
The proposed technology has superiority over the existing platform technologies
The proposed technology is preferably applicable to evaluation/analysis of various combinations of genes and drugs, and multiple drugs, in addition to that of two synthetic lethal genes
(2) Novel synthetic lethal factor
A proposal on novel synthetic lethal factors is also welcome.
Factors must be discovered using proposer’s technology platform* or evaluation system. * In this case, it does not necessarily have to satisfy the requirements for technology platform listed in (1).
Items to be Submitted
Anticipated Project Process
After the preliminary screening of documents, the Client will ask additional questions to promising proposals and conduct direct discussions to select candidates for the final selection. During the selection process, the Client may execute NDA with selected respondents, seek further information disclosure, and discuss specific development targets or potential opportunities. Specifics of any collaboration will be determined through consultation with the concerned parties.
Notes on Response
Proposal shall have clear points and should not include confidential information. Supplemental files may be submitted in addition to the proposal.
The client will evaluate all responses with the following criteria.
Overall scientific and technical merit
Approach to proof of concept or performance
Economic potential of concept
Realism of the proposed plan (action items, timeline, roles, deliverables, cost estimation)